問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
郭鈞瑋
下載
2024-05-21 - 2029-02-22
Condition/Disease
Test Drug
Participate Sites8Sites
Not yet recruiting1Sites
Recruiting7Sites
2022-11-30 - 2027-10-31
Participate Sites9Sites
Recruiting9Sites
2022-03-01 - 2028-04-30
2025-09-01 - 2028-09-30
Participate Sites5Sites
Recruiting5Sites
2023-04-01 - 2026-12-31
Participate Sites7Sites
Not yet recruiting5Sites
Recruiting2Sites
2023-03-01 - 2026-10-30
HER2 Mutant Non-small Cell Lung Cancer
ELVN-002ENHERTUKADCYLA
Participate Sites3Sites
Recruiting3Sites
2023-07-07 - 2025-12-31
Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma
ABBV-514ABBV-181 (Budigalimab)
全部
